Kornimate/medical-research-clean huggingface dataset:
getting informed and living well among asian americans in california

Conditions: COVID-19; Well-Being, Psychological

Summary: the project is to facilitate pandemic recovery by promoting emotional wellness among asian californians. the intervention includes a 6-week program in which participants may choose to receive text only or text + lay health worker outreach targeting 600 self-identified asian americans residing in california who speak/read english, chinese, korean, hmong, or vietnamese.

investigators will conduct a non-randomized intervention trial (preference trial). research participants involved in the trial will include 20 lay health workers (lhws) and 600 trial participants with intervention delivered via sms text messaging (for all participants), and the intervention group will receive educational intervention outreach from an lhw via zoom or mutually agreed video conferencing online venues, and by telephone or instant messaging. participants will choose which group they are in, sms text messaging only or sms text messaging plus educational outreach from an lhw.

Eligibility criteria:
inclusion criteria: i) age 18 and older ii) speak chinese, english, hmong, korean, or vietnamese iii) self-identify as asian american iv) have access to a mobile phone to receive sms text messages exclusion criteria: * unwilling to receive sms text messages from the project

Keywords: asian americans peer education immigrants chinese hmong korean vietnamese
efficacy of albumin therapy with standard medical treatment (smt) as compared to standard medical treatment (smt) in improving patient survival and immune modulation in patients with acute on chronic liver failure (asia trial).

Conditions: Acute on Chronic Liver Failure

Summary: the aim of the study is to study the efficacy of intravenous albumin and standard medical treatment as compared to standard medical treatment alone in ameliorating/preventing sirs and improving survival at 28 days .the project will be conducted in ilbs from august 2018 to december 2019concept is to understand the immunology, pathophysiology and effects of albumin in the management of aclf for betterment of the patient's condition and early recovery. all aclf patients will be included as per the inclusion and exclusion criteria , after taking informed consent from the patient or their relatives. will be evaluated for the possible risk factors for the development of sirs/sepsis in aclf patients and possible beneficial factors for resolution of sirs /sepsis in aclf patients. the effects of albumin administration as per this protocol versus standard medical treatment alone will be reviewed if patient develops allergic reactions to albumin, fluid overload, albumin will be stopped and patient will be treated accordingly to medical condition.


Eligibility criteria:
inclusion criteria: 1. age \>18 years to 65 years 2. aclf patients exclusion criteria: 1. patients who have already received albumin in last 1 week 2. patients who require albumin like picd (paracentesis-induced circulatory dysfunction) ,sbp (spontaneous bacterial peritonitis),lvp(large volume paracentesis),hrs(hepatorenal syndrome) 3. not given consent 4. significant cardiopulmonary or structural heart disease/ ckd(chronic kidney diseses) /volume overload /upper gi bleed. 5. pregnant/ hiv / hcc \>2cm size 6. alcoholic hepatitis eligible for steroids 7. previous known allergic/adverse reaction to albumin 8. any clinical condition which the investigator considers would make the patient unsuitable for the trial 9. patients who will receive palliative treatment only during their hospital admission
single-center, prospective study on the identification and delineation of brain and lung tumors and at-risk organs, and functional testing of surrounding tissues based on dual-energy ct

Conditions: Image Quality and Contouring Accuracy of the Tumor in Radiotherapy

Summary: this study explored the feasibility of dual-energy ct in head and lung tumors. dual-energy ct can achieve quantitative ct imaging based on traditional imaging by dual-energy spectral imaging, and enhance the clarity of head and lung tumors. in this study, we will prospectively explore the image accuracy and delineation accuracy of dual energy ct in radiotherapy to verify whether dual energy ct performs better with conventional ct.


Eligibility criteria:
inclusion criteria: 1. voluntarily participate in and sign the informed consent in person. 2. over 18 years old, gender unlimited; 3. after imaging diagnosis of primary lung cancer or space-occupying lung lesions with oligometastases, mdt decided to treat sbrt 4. clinical stage ia-iv (ct1-4n1-3m0-1); 5. no serious abnormality of blood system, heart, lung, liver, kidney function and immune deficiency; 6. coagulation function: activated partial thromboplastin time (aptt) \ 3 months;13, can acquire mri scanning exclusion criteria: 1. patients could not tolerate or were unwilling to undergo ct examination; 2. the primary lesion has undergone surgery or radiotherapy or chemotherapy or targeted or immunotherapy; 3. subjects who have received other drug trials within the last 1 month; 4. people with severe allergic history or idiosyncrasies; 5. patients with a history of severe lung or heart disease; 6. severe comorbidities, such as uncontrolled hypertension, heart failure, etc.; 7. pregnant or lactating women; 8. previous history of malignant tumor; 9. refusal or inability to sign informed consent to participate in the trial; 10. currently or planning to participate in other clinical trials; 11,can not acquire mri scanning
intravenous n-3 fatty acids and ventricular tachycardia in patients with implantable cardioverter defibrillator (icd)-pacemaker

Conditions: Ventricular Tachycardia; Sudden Cardiac Death

Summary: the long-chain n-3 polyunsaturated fatty acids (pufa), eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), appear to offer protection against sudden cardiac death and ventricular arrhythmias. epa and dha are essential fatty acids which are incorporated into cellular membranes after regular ingestion of fatty fish or fish oil. this study investigates a possible acute effect of intravenous infusion of n-3 pufa on inducibility of ventricular tachycardia (vt) in patients with an icd-pacemaker. the hypothesis is that an acute rise in the concentration of n-3 pufa in plasma will increase the electric stability of the myocardial cells, so that vt is more difficult to induce. in a randomized, placebo-controlled, double-blind, crossover study, a lipid emulsion with a high content of n-3 pufa (or placebo: isotonic saline) will be administered intravenously before a non-invasive electrophysiologic examination performed via the icd and following a predefined protocol. the main outcome is inducibility of vt. if sustained vt is induced in a patient after both n-3 pufa and placebo, the strength of the required stimulus after n-3 pufa and after placebo is compared.


Eligibility criteria:
inclusion criteria: * sustained ventricular tachycardia (vt) inducible during primary electrophysiological study (before icd implantation) and one of the following * latest vt episode terminated by anti-tachycardia pacing (atp) * vt induced during primary electrophysiological study terminated by atp exclusion criteria: * premenopausal women * allergy to fish or egg protein * blood pressure \> 160/90 (treated or untreated) * mi, pci or cabg within the previous 6 months * hba1c \> 10% * alt \> 150 u/l * inr \> 3.5 * plasma-potassium \< 3.5 mmol/l * fasting triglycerides \> 3 mmol/l * other serious illness * inability to sign informed consent

Keywords: icd-pacemaker
flt pet/mr for evaluation of pseudoprogression in patients with brain lesions

Conditions: Brain Lesions; Brain Metastasis; Brain Metastases

Summary: this is a single arm, single center study of 15 patients with brain lesions being treated at unc hospitals. subjects will undergo one (1) flt-pet-mri scan before their scheduled surgical biopsy of their brain lesion(s).

identifying imaging biomarkers of metastatic brain tumor treatment response could allow early modification of treatment by determination of tumor progression vs. treatment related effects (pseudo-progression, radiation necrosis). earlier treatment response assessment could reduce cost, improve clinical trial efficiency and allow better assessment of prognosis. the development of pet/mri offers the possibility of combining the functional imaging of pet with the exquisite soft tissue contrast and physiologic imaging capabilities of mri. combining flt-pet imaging with mri may allow better evaluation of new and unclear lesions in brain metastatic disease. the goal of this study is to explore flt-pet imaging combined with dynamic mr imaging techniques for the identification of tumor response markers in metastatic brain tumors.

Eligibility criteria:
inclusion criteria: * known brain lesion in central nervous system (cns) scheduled to have surgical biopsy of the lesion, identified by the unc brain tumor board as having clinical question of radiation necrosis vs. recurrence * at least one measurable lesion greater than 1 cm in diameter * ≥ 18 years of age * study-specific informed consent reviewed and signed exclusion criteria: * pregnant, nursing, or planning to become pregnant within 30 days of anticipated pet-mri scan * condition that makes mri unsafe (e.g., cardiac pacemaker, epicardial pacemaker leads, cochlear implants, metal aneurysm clips, metal halo devices) * inability to tolerate mri (e.g., unable to lie flat for \> 1 hour, severe claustrophobia) * allergy to mri contrast agent (magnevist, multihance, ablavar, dotarem, eovist, gadavist) * known allergy to fluorothymidine * study participation would cause significant delay (\> 2 weeks) in scheduled standard of care therapy * creatinine clearance \< 60 ml/min, as estimated by the cockcroft-gault formula * body mass index (bmi) \> 35 * poorly controlled diabetes mellitus (fasting blood glucose \> 200 mg/dl)
artemether-lumefantrine clinical effectiveness study

Conditions: Parasitologically Confirmed; Malarial

Summary: in 2009, papua new guinea officially adopted artemether-lumefantrine (al) as new national first-line drug for uncomplicated malaria. the principal purpose of this study is to measure the absolute effectiveness of al when used under real-life clinical conditions, as compared to optimized in-vivo trial conditions. this question was raised by the national department of health in preparation for the country-wide roll-out of al. the study is designed as a randomized controlled trial comparing two study arms. patients in the "effectiveness arm" receive the first dose of al under full supervision in the clinic; the following doses will be taken at home, as in real-life clinical practice and according to the new national treatment guidelines. patients in the "efficacy arm" will receive all doses of al as directly observed treatment in the clinic in order to establish the efficacy of the drug when used under ideal conditions. the study will enroll outpatients aged 6 months to 10 years with a history of fever and a positive rapid test for malaria. patients meeting all enrollment criteria and providing full written informed consent by a parent/caretaker will be randomized into either of the two study arms. patients in both arms will be followed up actively for 42 days. patients in the efficacy arm will be scheduled for visits on days 0, 1, 2, 3, 7, 14, 28 and 42; patients in the effectiveness arm on days 0, 3, 7, 14, 28 and 42.


Eligibility criteria:
inclusion criteria: * age 6 months to 10 years (+/- 1 month for children without known date of birth) * permanent resident in the study area * not enrolled in another study at the same time * no known history of hypersensitivity reactions to artemether or lumefantrine * history of fever in the previous 72 hours (approximate) * rapid diagnostic test (rdt) positive for any species of plasmodium exclusion criteria: * general danger signs: inability to drink or breastfeed, vomiting everything, recent history of convulsions, lethargy or unconsciousness, inability to sit or stand up * signs of severe malaria (impaired consciousness, respiratory distress, circulatory collapse, abnormal bleeding, jaundice, or as determined by clinician) * severe malnutrition: defined as a child whose weight-for-height is below -3 standard deviation or less than 70% of the median of the nchs/who normalized reference values, or who has symmetrical oedema involving at least the feet; or middle upper arm circumference under 12 cm * clinically significant concomitant disease requiring admission * contraindications mentioned in the national treatment guidelines

Keywords: malaria plasmodium papua new guinea artemether/lumefantrine
a development of inflammatory bowel disease pattern identification algorithm using case series data

Conditions: Inflammatory Bowel Diseases

Summary: this study aimed to identify inflammatory bowel disease (ibd) patterns based on presenting symptoms and to suggest algorithms for determining pattern and herbal prescriptions for corresponding patterns. the investigators collected symptom data of 67 ibd patients who achieved and maintained clinical remissions after they had taken herbal medicine prescriptions. prescriptions were categorised into 5 patterns, which were named after main features and symptoms of included patients. associations between presenting symptoms and patterns were visualised using a term frequency inverse document frequency (tf-idf) method. determining ibd patterns from symptoms of patients was analysed and charted by decision tree modeling.

herbal prescriptions are one of the most sought complementary and alternative medicine treatment strategies for inflammatory bowel disease patients. however, variability in pattern identification of traditional chinese medicine (tcm)/traditional east asian medicine (team) has been criticised. using data of patients who achieved and maintained clinical remission after tcm/team herbal medicine prescription, the investigators aimed to develop treatment algorithms refined by identified pattern and key symptoms which practitioners can easily discriminate. based on herbal prescriptions which induced clinical remission, ibd patients were divided into 5 patterns, i.e., large intestine type, water-dampness type, respiratory type, upper gastrointestinal (gi) tract type, and coldness type. by term frequency-inverse document frequency (tf-idf) method, the association between 22 symptoms that were described as indications of the herbal medicine prescriptions and 5 patterns were analysed. decision tree modeling was used for prediction of relevant patterns from symptoms.

Eligibility criteria:
inclusion criteria: * diagnosis of ibd by gastroenterologist * patients have achieved and maintained clinical remission of ibd symptoms after they took herbal prescriptions * patients have provided written informed consent exclusion criteria: * details regarding any of 25 symptoms were omitted

Keywords: herbal prescription herbal medicine pattern identification algorithm decision tree tf-idf
prevalence of pulmonary hypertension in copd patients

Conditions: COPD; Pulmonary Hypertension

Summary: the prevalence of an increased pulmonary blood pressure amongst patients with chronic obstructive pulmonary disease (copd)is unclear. so is the impact of abnormal pulmonary blood pressure on symptoms. the aim of this study is to determine the prevalence of an increased pulmonary blood pressure in 200 patients with copd. furthermore we will investigate if lung function test results and blood tests can predict an increased pulmonary blood pressure, and explore whether copd patients with a high pulmonary blood pressure have more symptoms that their co-patients.

the prevalence of pulmonary hypertension in patients with chronic obstructive pulmonary disease (copd) is unclear. the presence of an abnormally increased pulmonary blood pressure worsens the prognosis of copd, but the patients are not currently diagnosed or treated for pulmonary hypertension. the aim of this study is to determine the prevalence of pulmonary hypertension in 200 patients with copd and explore whether it worsens functional capacity and symptoms. furthermore we will look into whether blood gas values, nt-probnp, crp and lung function test result can predict which patients are at risk of having pulmonary hypertension. methods: all patients will be screened by echocardiography. those with signs of pulmonary hypertension will be admitted to right heart catheterization for direct measurements of pulmonary haemodynamics. all patients will perform a 6 minutes walk test and spirometry. blood levels of nt-probnp and crp will be measured. life quality by the st. george questionnaire and contacts to the health care system is also assessed. differences in these parameters are analyzed among patients with no, moderate or severe pulmonary hypertension.

Eligibility criteria:
inclusion criteria: * diagnosis of copd * prior admittance to hospital with exacerbation in copd * informed consent exclusion criteria: * exacerbation in copd less than 6 weeks before examination

Keywords: copd pulmonary hypertension nt-probnp 6 minutes walk test
the use of fdg-pet in patient with hodgkin lymphoma: a population based study from northern italy

Conditions: Histologically Confirmed Classical Hodgkin Lymphoma According to the Current World Health Organisation Classification

Summary: positron emission tomography (pet) represents a step forward in the definition of response to therapy in patients with hodgkin lymphoma (hl). in particular the use of pet for the early assessment of response has been described as the most important tool for predicting the risk of disease progression. as no data are available to support the use of early assessment of response for adapting and modifying subsequent treatment, the use of pet should be limited only to patients enrolled in clinical trials. irrespective of recommendations pet scanning is included in the current management of patients with hl at baseline, mid treatment, end of treatment, and follow-up. so far no study has been performed to verify how pet is currently used in the clinical setting and to assess if and how results of pet scanning are used for supporting treatment and clinical decisions.


Eligibility criteria:
inclusion criteria: 1. histologically confirmed classical hodgkin lymphoma according to the current world health organisation classification (nodular sclerosis, mixed cellularity, lymphocyte rich, lymphocyte depleted). 2. clinical stage i-iv. 3. no previous chemotherapy, radiotherapy or other investigational drug for hl. exclusion criteria: 1. none.

Keywords: hodgkin lymphoma fdg-pet prognostic factor clinical trial
tomoelastography in predicting postoperative pancreatic fistula

Conditions: Pancreatectomy

Summary: postoperative pancreatic fistula (popf) is a prevalent and severe complication of pancreaticoenteric anastomosis; however, its accurate preoperative prediction is challenging. multi-frequency mr elastography-based tomoelastography can quantify pancreatic mechanical properties (stiffness and fluidity), thus further improving the predictive performance of conventional mri for postoperative pancreatic fistulas.


Eligibility criteria:
inclusion criteria: participants diagnosed with postoperative pancreatic fistula who underwent both preoperative multi-frequency mre and pancreaticoenteric anastomosis were included in the study. - exclusion criteria: without appropriate image quality； without available pathological data -
immediate intra uterine isemination (iui) versus expectant management in postoperative endometriosis patients

Conditions: Endometriosis; Infertility

Summary: is postoperative iui better than expectant management in infertile endometriosis patients with good prognosis based on their efi score? (a single centre randomised controlled trial).


Eligibility criteria:
inclusion criteria: * recent (\<6months) complete laparoscopic endometriosis resection * endometriosis fertility index (efi) at least 7/10 * regular menstrual cycles (min 24days - max 38days) with proven ovulation * at least one functional tube at surgery, normal uterus * sperm sample of partner: normal or mild male factor exclusion criteria: * frozen (donor or partner) sperm * clinical and/or imaging evidence of endometriosis recurrence/persistence at randomization * fsh \> 20 iu/l

Keywords: infertility endometriosis
the effects of endotracheal suctioning on pain and serum markers

Conditions: Intensive Care Unit ICU; Intubation; Critical Illness; Mechanical Ventilation; Pain Measurement; Pain, Procedural; Oxidative Stress; Hypoxia; Biomarkers / Blood; Adult; Uric Acid; Sepsis; COVID; Influenza; Pneumonia

Summary: the goal of this experimental study is to understand if endotracheal tube (ett) suctioning increases pain and causes stress on the body in intubated adult icu patients. these patients are already on ventilators, which means they need suctioning to keep their airways clear, but this procedure may be uncomfortable and cause stress. the main questions this study aims to answer are: does ett suctioning raise pain levels as measured by the critical-care pain observation tool (cpot)? does ett suctioning increase certain chemicals in the blood (hypoxanthine, xanthine, and uric acid) that show stress and lack of oxygen in the body? researchers will compare patients who have ett suctioning (intervention group) with those who do not have suctioning during the study period (control group) to see if there are differences in pain and blood markers of stress. participants will: have pain measured before and after suctioning using the cpot. have blood samples taken from an existing line at three time points: 5 minutes before, 5 minutes after, and 30 minutes after suctioning. provide demographic information (like age, gender, and diagnosis) from medical records. this research will help improve how pain is managed for icu patients who cannot speak for themselves, potentially leading to better pain relief methods in the future.


Eligibility criteria:
inclusion criteria: * adults (aged 18 years and older) * current diagnosis of flu, pneumonia, covid, or sepsis * intubated and receiving mechanical ventilation. * have arterial lines placed * require endotracheal suctioning as part of their care exclusion criteria: * patients receiving neuromuscular blocking agents * contraindications for blood draws (hemoglobin levels below 8.0 g/dl; jehovah's witness)